New oral anticoagulants: Discussion on monitoring and adherence should start now!

Thrombosis Journal

Volumn 11, Issue 1, 2013, Pages

  ten Cate, Hugo ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adherence; Laboratory assays; New oral anticoagulants; Vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARDIOVASCULAR AGENT; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD PRESSURE MONITORING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DOSE CALCULATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG STABILITY; EDITORIAL; ELDERLY CARE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; MEDICATION COMPLIANCE; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PROTHROMBIN TIME; VENOUS THROMBOEMBOLISM;

EID: 84879443899     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-11-8     Document Type: Editorial

References (42)

1. Deykin D. Warfarin therapy. N Engl J Med 1970, 283(13):691-694. Review, 10.1056/NEJM197009242831307, 4916914.
2. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992, 102(4 Suppl):312S-326S.
3. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. American College of Chest Physicians Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e44S-e88S. 3278051, 22315269, American College of Chest Physicians.
4. Ezekowitz MD, James KE, Radford MJ, Rickles FR, Redmond N. Initiating and maintaining patients on warfarin anticoagulation: the importance of monitoring. J Cardiovasc Pharmacol Ther 1999, 4:3-8. 10.1177/107424849900400102, 10684518.
5. Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000, 31:828-833. 10.1161/01.STR.31.4.828, 10753983.
6. Ageno W, Turpie AG, Steidl L, Ambrosini F, Cattaneo R, Codari RL, Nardo B, Venco A. Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement. Am J Cardiol 2001, 88:40-44. 10.1016/S0002-9149(01)01582-X, 11423056.
7. Ginsberg JS, Bates SM, Oczkowski W, Booker N, Magier D, MacKinnon B, Weitz J, Kearon C, Cruickshank M, Julian JA, Gent M. Low-dose warfarin in rehabilitating stroke survivors. Thromb Res 2002, 107:287-290. 10.1016/S0049-3848(02)00343-2, 12565715.
8. Buchanan-Leel B, Levetan BN, Lombard CJ, Commerford PJ. Fixed-dose versus adjusted-dose warfarin in patients with prosthetic heart valves in a peri-urban impoverished population. J Heart Valve Dis 2002, 11:583-592. discussion 593.
9. Herlitz J, Holm J, Peterson M, Karlson BW, Haglid Evander M, Erhardt L. LoWASA study group Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. Eur Heart J 2004, 25:232-239. 10.1016/j.ehj.2003.10.026, 14972424, LoWASA study group.
10. Perret-Guillaume C, Wahl DG. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose-a meta-analysis. Thromb Haemost 2004, 91(2):394-402.
11. Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy 2011, 31:1175-1191. 10.1592/phco.31.12.1175, 22122180.
12. Connoly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrium fibrillation. N Engl J Med 2009, 361:1139-1151. 10.1056/NEJMoa0905561, 19717844.
13. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrilation. N Engl J Med 2011, 365:883-891. 10.1056/NEJMoa1009638, 21830957, ROCKET AF Investigators.
14. Granger CB Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992. 10.1056/NEJMoa1107039, 21870978.
15. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. RE-COVER Study Group Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352. 10.1056/NEJMoa0906598, 19966341, RE-COVER Study Group.
16. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. EINSTEIN' Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297. EINSTEIN' Investigators.
17. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510. EINSTEIN Investigators.
18. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomized controlled trials. BMJ 2012, 345:e7498. 10.1136/bmj.e7498, 3496553, 23150473.
19. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008, 47:285-295. 10.2165/00003088-200847050-00001, 18399711.
20. Stangier J, Stiehle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008, 47:47-59. 10.2165/00003088-200847010-00005, 18076218.
21. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010, 30:1885-1889. 10.1161/ATVBAHA.110.203604, 20671233.
22. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011, 9:2168-2175. 10.1111/j.1538-7836.2011.04498.x, 21972820.
23. Freyburger G, Macouillard G, Lebrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011, 127:457-465. 10.1016/j.thromres.2011.01.001, 21277622.
24. Samama MM, Guinet C, Le Flem L, Ninin E, Debue JM. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 2013, 35:140-146. 10.1007/s11239-012-0803-x, 23335022.
25. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013, 109:127-136.
26. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther 2007, 45:335-344.
27. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011, 338:372-380. 10.1124/jpet.111.180240, 21515813.
28. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 2012, 26:27-32. 10.1111/j.1472-8206.2011.00981.x, 21848931.
29. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, Lacreta F. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013, 75:476-487. 10.1111/j.1365-2125.2012.04369.x, 3558798, 22759198.
30. Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost 2012, 107:916-924. 10.1160/TH11-09-0634, 22398784.
31. He K, Luettgen JM, Zhang D, He B, Grace JE, Xin B, Pinto DJ, Wong PC, Knabb RM, Lam PY, Wexler RR, Grossman SJ. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet 2011, 36:129-139. 10.1007/s13318-011-0037-x, 21461793.
32. Pradaxa product monograph, revised 2012, http://www.boehringeringelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/Pradax-pm.pdf.
33. http://www.zakboek-dabigatran.nl (table 6.1, page 34; webpage in Dutch).
34. Zakboek Rivaroxaban (Xarelto) Table 4, page 28 (Dutch language) 2012, Netherlands: Van Zuiden Communications BV, Zakboek Rivaroxaban (Xarelto).
35. Kowey PR, Naccarelli GV. The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out. Am J Med 2012, 125:732. 10.1016/j.amjmed.2011.10.035, 22608987.
36. Leidraad begeleide introductie nieuwe orale antistollingsmiddelen 2012 (in Dutch). http://www.orde.nl/assets/structured-files/Downloads/Leidraad+NOAC.pdf.
37. Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, Daniel JG, Ekman I, Ho M, Johnson M, Kimmel SE, Liu LZ, Musaus J, Shrank WH, Whalley Buono E, Weiss K, Granger CB. Medication adherence: A call for action. Am Heart J 2011, 162:412-424. 10.1016/j.ahj.2011.06.007, 21884856.
38. World Health Organization Adherence to long-term therapies: evidence for action. 2010, http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html, World Health Organization.
39. Baroletti S, Dell'Orfano H. Medication adherence in cardiovascular disease. Circulation 2010, 121:1455-1458. 10.1161/CIRCULATIONAHA.109.904003, 20351303.
40. Harenberg J, Marx S, Erdle S, Kremer R. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need. Expert Rev Hematol 2012, 5:107-113. 10.1586/ehm.11.79, 22272710.
41. Samama MM, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012, 130(Suppl 1):S88-S89.
42. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013 Jan 24, [Epub ahead of print].